AI-assisted, human-published
07/13/2026 /M & A
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion
Servier completes the acquisition of Edgewise Therapeutics' muscular dystrophy business, enhancing its rare neurology pipeline with the addition of sevasemten and advancing its 2030 ambition.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com